Navigation Links
Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference
Date:10/29/2008

y on cancer and various women's health indications. The company expects that the first microRNA diagnostic tests applying its technology will be launched by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the expected timing of submission for approval and launch of diagnostic tests using our microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtai
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
2. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
3. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
4. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
5. Rosetta Genomics Reports Second Quarter 2008 Financial Results
6. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
7. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
8. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
9. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
10. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
11. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... cell culture products, announces the availability of BI’s line of human mesenchymal stem ... these stem cell differentiation media offer a complete system for multipotency evaluation of ...
(Date:7/28/2015)... ... ... new Xsample 530 sample changer for vials can be used with Anton Paar ... less than 12,000 mPas (internal air) up to 36,000 (external air) – and can process ... about Xsample 530 is its removable magazine, which is easily lifted off its hub and ...
(Date:7/28/2015)... , July 21, 2015 ... has announced the addition of the "Analysis ... report to their offering. Globally, flow ... including immuno-phenotyping, cell proliferation, cancer, and stem cells. ... clinical applications primarily because of demand from underdeveloped ...
(Date:7/28/2015)... SAN DIEGO , July 28, 2015  Kerastem ... conditional approval from the U.S. FDA Center For Biologics ... Gene Therapies to conduct a clinical trial investigating the ... treatment of female and early male pattern baldness (androgenic ... the STYLE trial, follows initial clinical work in ...
Breaking Biology Technology:Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3New Moves in Automatic Sample Handling: Introducing Xsample 530 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2
... highly-sensitive golf clubs, developed by scientists, regularly catch the ... Rory McIlroy get excited this time, this new golf ... The ,micro putter, developed in a study published ... Science and Technology, has been designed to test the ...
... TUCSON, Ariz., Oct. 4, 2011 The VENTANA anti-Helicobacter ... the first H. pylori antibody ... Administration (FDA). Developed by Ventana Medical Systems, Inc. (Ventana), ... pylori antibody, when used in immunohistochemical (IHC) staining, aids ...
... Heart Failure Society of America,s 15th Annual Scientific Meeting, ... that B-type natriuretic peptide (BNP) may have utility in ... decompensation in advance of acute presentations.   ... by Alere Inc., is the first of its kind ...
Cached Biology Technology:Scientists take up golf to prove long-standing theory of cell stickiness 2Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody 2Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody 3HABIT Study Highlights Home BNP Testing May Allow for Earlier Interventions and Better Management of Heart Failure Patient 2HABIT Study Highlights Home BNP Testing May Allow for Earlier Interventions and Better Management of Heart Failure Patient 3
(Date:7/8/2015)... NEW YORK , July 8, 2015  BD ... announced BD & Guidepoint Mentor, a new ... to Guidepoint,s expert network services. BD ... technologies to improve healthcare delivery and outcomes and, with ... start-up entrepreneur will be able to directly engage with ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... possible health and environmental effects of oil dispersants in the ... today described a new dispersant made from edible ingredients that ... to the feathers of birds. "Each of the ingredients ... peanut butter, chocolate and whipped cream," said Lisa K. Kemp, ...
... Calif., August 20, 2012 The underlying causes of ... deal of evidence points to the accumulation of β-amyloid, ... formed by the activity of several enzymes, including one ... of BACE1, which in turn leads to more brain-damaging ...
... 20, 2012  The board of directors of Westlake Chemical Corporation ... of 18.75 cents per share, an increase of over 150% ... quarter of 2012. The increased dividend will be payable on September ... This is the 32nd successive quarterly dividend that ...
Cached Biology News:New oil spill dispersant made from ingredients in peanut butter, chocolate, ice cream 2Brain enzyme is double whammy for Alzheimer's disease 2
... whose sequence is from the C-terminal end of the mouse retinoic acid ... acids 429 to 448 of RAR*. The sequence of PEP-005 is ... S - P - S - S - V - E - ... S - P - L - L - Q (The N-terminal ...
... with Medium High quality ready-to-use cryopreserved neural ... medium for growth and lineage commitment. Just ... from E18 fetal rat brain in the ... of in vitro stem/progenitor cells, neurons, astrocytes ...
... use of small interfering RNA (siRNA) molecules ... interference (RNAi) pathway have generated tremendous interest ... siRNA for experimental use can be synthesized ... then transfected into the target cells in ...
... use of small interfering RNA (siRNA) molecules ... interference,(RNAi) pathway have generated tremendous interest in ... for experimental use can be,synthesized in vitro, ... into the target cells in vitro or ...
Biology Products: